Skip to main content

2019 Medical Supply Bulletins

Stay up to date on PSC medical supplies. Our bulletins are an easy way to find out about updates and to keep you informed about all our products and services.

Medical Supply Bulletins.

January 11, 2019

Hepatitis B Vaccines Currently Available

PSC has a number of hepatitis B vaccines currently available for purchase or that we will be stocking in the future. We will also be adding a two-dose hepatitis B vaccine, HEPLISAV-B, to our supply stock. (Detailed information on HEPLISAV-B follows the two availability charts.)

Please be aware there are a number of hepatitis B vaccines that are unavailable through the U.S. Department of Health and Human Services (HHS) Supply Chain Management Services. This is due to the adult formulation for these vaccines is not anticipated to be available throughout 2019. We will update the supply status with the latest information as it is available.

Hepatitis B Vaccines Available for Purchase

Product NDC MFG Notes SCMS Item Number

HEP-B VAC,20MCG/
0.5ML,PFS,
HEPLISAV-B,5S

43528-
0003-05

Dynavax Technologies Corporation

Will have 2+ years dating when manufactured

6505000000400

TWINRIX,HEP A & HEP B,PFS,TIP-LOK,10S

58160-
0815-52

GlaxoSmithKline

 

6505000007903

NABI-HB HEP B IMMUNE/GLOB, SDV,5ML

59730-4203-01

Biotest Pharmaceuticals

 

6505010526862

ENGERIX-B,HEP B,20MCG/MG,1ML, SDV,10S

58160-0821-11

GlaxoSmithKline

 

6505015590924

ENGERIX-B,HEP B, 20MCG/ML,PFS, TIP-LOK,10S

58160-0821-52

GlaxoSmithKline

 

6505015990546

 

Hepatitis B Vaccines NOT Available

Product NDC MFG Notes Item Number
RECOMBIVAX HB® [Hepatitis B Vaccine (Recombinant)] – Adult Formulation 00006-4094-02 Merck Adult formulation is not anticipated to be available in 2018. Supply status will be updated with latest information, as available. 6505000007615
RECOMBIVAX HB® [Hepatitis B Vaccine (Recombinant)] – Adult Formulation 00006-4995-00 Merck Adult formulation is not anticipated to be available in 2018. Supply status will be updated with latest information, as available. 6505015029962
RECOMBIVAX HB® [Hepatitis B Vaccine (Recombinant)] – Adult Formulation 00006-4995-41 Merck Adult formulation is not anticipated to be available in 2018. Supply status will be updated with latest information, as available. 6505000006505
 

Recently Added to Our Supply Stock - HEPLISAV-B

  • Is indicated for prevention of infection caused by all known subtypes of hepatitis B virus.
  • Is approved by the FDA for use in adults 18 years of age and older.
  • Is administered as two doses by intramuscular injection in the deltoid region, one month apart.
  • Is available in pre-filled syringes and will have two plus (2+) years dating when manufactured.
  • HEPLISAV-B provided statistically higher rates of protective immunity to 90 percent or more compare to three doses of Engerix-B in healthy patients and in those groups known to be hypo-responsive to hepatitis B immunization (older adults >40 years of age, men, persons with diabetes, obese persons, and persons who smoke)
  • Local injection site reactions and systemic adverse events were similar compared to Engerix-B in clinical trials
  • Adherence to three-dose hepatitis B vaccines has been reported between 40 to 54 percent (privately insured). Recent data from the Centers for Disease Control and Prevention (CDC) report 22 percent for a three-dose series completion in the public health setting.
  • The shortened series of Heplisav B as two doses, one month apart, should improve patient adherence and offer faster protective levels in high-risk populations.
  • An increase in acute hepatitis B cases has been reported in some states due to the recent opioid crisis.
  • Viral hepatitis B is a risk factor for the development of liver cancer, which is on the rise in the United States.

Additional Information

Always, consult the package insert for precautions, warnings, and contraindications. You can also visit the CDC hepatitis B vaccine safety page for additional information, including information on possible side effects.

 

TO THE TOP